Formulation and Evaluation of Fluvoxamine Maleate Loaded Lipid Nanoparticle

DOI:

https://doi.org/10.37285/ijpsn.2019.12.4.5

Authors

  • Ashok Kumar P
  • Mancy S.P.
  • Manjunath K
  • Suresh V. Kulkarni
  • Jagadeesh R

Abstract

Recently solid lipid nanoparticles (SLN's) have been received much attention by the researchers owing to its biodegradability, bioavailability and the ability to deliver wide range of drugs to the targeted site of action. The purpose of the present study is to develop and evaluate the fluvoxamine maleate loaded lipid nanoparticles. The fluvoxamine maleate lipid nanoparticles (LN’s) were prepared by the hot melt homogenization followed by the sonication by using different combination of lipids like tristearin, compritol, olive oil, coconut oil, sesame oil. Compatibility study was confirmed by FTIR and DSC. The LN’s were evaluated for particle size, PDI, zeta potential, entrapment efficiency and in-vitro drug release. For the Fluvoxamine maleate LN’s prepared using the solid lipids, the particle size ranged from 98.58 to 152.43 nm. PDI of all formulations were good within the range of 0.239 to 0.456 with zeta potential from - 6.52 to -18.6 mV. Entrapment efficiency observed was in the range of 64.56 to 84.23 %. The cumulative percentage release of fluvoxamine maleate from different LN’s varied from 46.14 to 81.48%. For the formulations prepared using the combination of solid lipids and liquid lipids, Fluvoxamine maleate LN’s the particle size ranged from 63.22 to 263.8 nm. With good PDI range from 0.229 to 0.514 Zeta potential of all formulation is from - 5.01 to -9.30 mV. Entrapment efficiency observed was in the range of 71.02 to 90.51 %. The cumulative percentage release of fluvoxamine maleate from different LN’s varied from 63.71 to 85.41% depending upon the drug lipid ratio, the type of lipid used. The release kinetic studies showed that the release was first order, diffusion controlled, and the ‘n’ values obtained from the Korsmeyer-Peppa’s model indicated the release mechanism was Anomalous (non-Fickian) diffusion type.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Fluvoxamine, solid lipid nanoparticles, lipid nanoparticles, in vitro drug release

Downloads

Published

2019-07-31

How to Cite

1.
P AK, S.P. M, K M, Kulkarni SV, R J. Formulation and Evaluation of Fluvoxamine Maleate Loaded Lipid Nanoparticle. Scopus Indexed [Internet]. 2019 Jul. 31 [cited 2024 Nov. 19];12(4):4593-600. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/308

Issue

Section

Research Articles

References

Abdelbary G and Fahmy RH (2009). Diazepam-loaded Solid lipid nanoparticles: Design and characterization. AAPS Pharm. Sci. Tech. 10(1): 211-219.
Ekambaram P, Sathali AAH and Priyanka H (2012). Solid Lipid Nanoparticles: A Review. Sci. Revs. Chem. Commun. 2(1): 80-102.
Ekambaram P and Abdul SAA (2011). Formulation and evaluation of solid lipid nanoparticles of Ramipril. J. Young. Pharm. 3(3): 216-220.
Fatima S, Abdel S, Seham AE, Azza AM, and Hussein OM (2016). Diflucortolone valerate loaded solid lipid nanoparticles as a semisolid topical delivery system. Bulletin of faculty of pharmacy, Cairo University. 54: 1-7.
Frieder A, Fersh M, Hainline R and Deligiannidis KM (2019). Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. CNS Drugs. 33(3): 265-282.
Gouda R, Himankar B, and Zhao Q (2012). Application of mathematical models in drug release kinetics of Carbido and Levodopa ER Tablets. J. Develop. Drugs. 6(2): 1-8.
Ketan P, Sameer P and Mangal N (2012). Duloxetine HCl Lipid Nanoparticles: Preparation, Charecterization, and Dosage Form Design. AAPS Pharm. Sci. Tech. 13(1): 125-133.
Kocbek, P, Baumgartner S, and Kristl J (2006). Preparation and evaluation of nanosuspension for enhancing the dissolution of poorly soluble drug. Int. J. of Pharmaceuticss. 312: 179-186.
Prathima S and Preethi, KS (2014). Formulation and evaluation of Gemcitabine Hydrochloride loaded solid lipid nanoparticles. J. of Global Trends in Pharmaceutical Sciences. 5(4): 2017-2023.
Rahul N, Ashok CKK, Vishnu KP, Chakrapani MY, and Prasanna YR (2012). Formulation and evaluation of chitosan solid lipid nanoparticle of carbamazepine; Lipids in Health and Disease. 11.72.
Ramteke KH, Joshi SS, and Dhole SN (2012). solid lipid Nanoparticle: A review. ISOR J. of. Pharm. 2(6): 34-44.
Saravanan D, Gobinath M, Balasubramamanian K, Jajakumar A, and Narasimhakumar M (2015). A new spectrophotometric method for the determination of fluvoxamine maleate in pure form and in pharmaceutical formulation. J. of Applied Pharmaceutical Sciences. 5(2): 81-86.
Sukhwinder S, Sukhmeet S K, Amith S, Daljit K, Manoj KK, Rajesh K (2018). Formulation and in-vitro Evaluation of solid lipid nanoparticles containing Levosulpiride. The Open Nanomed J 5: 17-29.
Yasir M and Udai VSS (2014). Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. Acta Pharmaceutica Sinica B 4(6): 454-463.